Us to deal with. And i love the way you two talked about whats happening and whats going to happen. Well, i mean, shes setting the tone for the administration. We have actually heard a lot from the new president in the past eight days. He has spoken publicly a lot. But we are hearing even more from jen psaki in the briefing room, and shes setting this tone of normalcy, accountability, Expository Work that tells us what the administration thinks the problem is, what they are doing to work on it, who is in charge of that work. And that person will be answering questions about it, as will jen psaki on behalf of the entire administration. Its just basic accountability, which is basic small deed democracy, which is just something we were used to before. We lost it for four years, and now it just feels so radical to get back to it. I hope it never i hope we never take it for granted again. I think we have, for this year, a series of rachel and jen conversations coming up at 9 00 p. M. Interm
PM Modi to meet seven Indian COVID-19 vaccine manufacturers on October 23 : Rashtra News #Modi #meet #Indian #COVID19 #vaccine #manufacturers #October Representatives from seven vaccine makers – Serum Institute of India, Bharat Biotech, Dr Reddy’s Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech – will be participating in the meeting. Prime Minister
Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade
Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda s goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda s existing facility in Germany and its partnership with IDT Biologika GmbH.